Skip to content

The Effects of Nicotine Chewing Gum in Parkinson's Disease

The Effects of Nicotine Chewing Gum on Acute Low Blood Pressure in Parkinson's Disease

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02452125
Acronym
PD
Enrollment
10
Registered
2015-05-22
Start date
2015-05-31
Completion date
2017-06-01
Last updated
2017-07-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Low Blood Pressure, Parkinsons Disease

Brief summary

The objective of this experiment is: To determine if nicotine chewing gum will improve acute episodes of orthostatic hypotension in PD subjects.

Detailed description

Subjects will be asked to sit and rest for 10 minutes. Blood pressure will be taken in this resting position after the 10 minutes. After all inclusion criteria has been met, subjects will then wear an automated BP cuff and be administered 4mg of nicotine gum (Nicorette™). They will be instructed to use it according to manufacturer's directions and remain chewing the gum for 30 minutes. The subject will remain in a seated position and BP and HR will be recorded every 5 minutes for 30 minutes. After 30 minutes the gum will be removed and subjects will still have HR and BP monitored in the seated position for another hour every 10 minutes. All values will be compared to pretreatment values. After 120 minutes if the subject is non-symptomatic, they can go home.

Interventions

DIETARY_SUPPLEMENTNicotine gum

Nicotine chewing gum

Sponsors

New York Institute of Technology
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* a diagnosis of PD * a diastolic BP less than 90 mmHg * and/or a systolic BP lower than 100mHg.

Exclusion criteria

* current tobacco users in all forms of tobacco * severe dysphasia (difficulty swallowing) * previous tobacco users who might be at risk for re-addiction.

Design outcomes

Primary

MeasureTime frame
Blood Pressure90 minutes

Secondary

MeasureTime frame
Heart Rate90 Minutes

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026